Addison Disease Testing Market Outlook (2023 to 2033)

The global Addison disease testing market is expected to garner US$ 249.8 million in 2023 and is likely to exhibit a CAGR of 3.4% to be valued at US$ 349.7 million in 2033. The introduction of the emergency card and growing healthcare spending are bolstering the demand for Addison Disease Testing across the globe, states Future Market Insights report.

Due to its mutable appearance, a high index of suspicion for Addison's disease is essential when assessing a conglomeration of non-specific symptoms. Thereby, early testing is necessary to provide better medical assistance to patients.

Attributes Details
Historical Value (2022) US$ 243.2 million
Current Year Value (2023) US$ 249.8 million
Expected Forecast Value (2033) US$ 349.7 million
Historical CAGR (2018 to 2022) 2.2%
Projected CAGR (2023 to 2033) 3.4%
Market Attraction The rising number of private diagnostic centers, the mounting awareness regarding Addison's disease, and initiatives taken by healthcare organizations and the government are likely to augment the demand for Addison's disease testing throughout the forecast period.

Addison’s disease also called chronic adrenocortical insufficiency occurs because of damage to the adrenal cortex resulting in insufficient production of the hormone cortisol & aldosterone. The disease is characterized by symptoms such as weight loss, decreased appetite, extreme fatigue, hyperpigmentation, low blood pressure, and several others.

Not treating the disease for long-time results in an Addisonian crisis which is a life-threatening medical emergency. People suffering from anticoagulants, cancer, chronic infections, and tuberculosis are more likely to be affected by the disease. Doctors look for the medical history and do a physical examination as well as various laboratory tests for diagnosing the disease.

Idiopathic autoimmune Addison's disease is found to be more common in children, females, and people within the age group of 3050 years. Delaying in diagnosis and treatment of the disease may lead to high chances of morbidity and mortality. Addison's disease is considered a rare disease in many parts of the world. The testing service includes a number of laboratory as well as imaging studies.

The market growth is primarily driven by

  • the increasing prevalence of Addison's disease worldwide
  • the growing awareness regarding adrenal insufficiency
  • rising healthcare expenditure in various countries

According to a June 2021 article, congenital adrenal hyperplasia affects around one in 10,000 newborns. Adrenal insufficiency disease is also caused by the rising number of tuberculosis cases. In 2021, the United States reported around 7,860 cases of tuberculosis. Furthermore, around 13 million people in the United States have latent tuberculosis infection. These factors are fueling the rise of adrenal insufficiency cases and impacting market growth.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

What are the factors propelling the Global Addison Disease Testing Market?

The increasing rate of adrenal insufficiency is also increasing cases of Addison's disease and thus increasing the testing service market. Increasing government initiatives in improving the healthcare sector and providing access to a large population with diagnostic service facilities increases the market. Furthermore, an increase in the number of private diagnostic service providers, will in turn increase the overall testing service market.

Besides, enhanced healthcare infrastructure in emerging countries and the swelling number of regulatory endorsements for immunoassay practices further drive the demand for Addison disease testing across the globe.

What are the Factors Hampering the Global Addison Disease Testing Market?

Limitation to accessing healthcare facilities in various parts of the globe curbs the market to growth. The ignorance of symptoms and lack of healthcare facilities for every segment of society also restrict the market.

Regional Analysis

Region 2022 Value Share in Global Market
North America 35.2%
Europe 27.7%

Why is North America Emerging as an Opportunistic Addison Disease Testing Market?

North America owing to high concerns for human health and growing awareness of the benefit of government initiatives in this direction thus represents the largest market for testing services. Nearly 1 in 100,000 people in the USA is affected by Addison’s disease. The global prevalence is projected to be between 40 and 60 people per million of the general population. The prominent reason behind this is that cases of Addison’s disease may go undiagnosed, and it is challenging to determine its accurate frequency in the general population. Thereby, several governments are running awareness programs and organizing medical camps to increase the testing percentage in the region.

For instance, In May 2020, the Addison self-help group celebrated International Addison’s day to improve the treatment of people with Addison's Disease and Adrenal Insufficiency and create awareness by starting several initiatives on social media. This group facilitates the sharing of emergency injection kit and encourage people to keep their kit with them at all times and normalize this potentially scary situation.

Besides, the increment in the Healthcare budget in the past two to three decades in the countries like USA & Canada has played an imperative role in the amplified testing and avail better medical facilities in the region. According to the Journal of American Medical Association (JAMA), healthcare expenditure in the USA upsurged nearly a trillion dollars in the past two decades. The association revealed that healthcare expenditure in the USA during 2020 was around $3.8 trillion, i.e., $11,000 per person. These expenditures are likely to be $6 trillion - nearly $17,000 per person by 2032.

Why is the demand for Addison Disease Testing Burgeoning in Europe?

This market growth is attributed to the higher prevalence rate and good diagnostic services available in the region. Several governments are running programs to form a strong healthcare platform for curing chronic diseases like Addison’s disease which impact millions.

For instance, In October 2014, during a conference of the European Council of Affiliated Societies (ECAS), the active countries launched uniform emergency care for patients affected by adrenal insufficiency. This card was made available for patients across the Europe region, thereby the demand for Addison disease testing is likely to surge in the coming years.

In 2022, the Addison’s Disease Self-Help Group (ADSHG) announced its sponsorship of 3 CoMICs team members to the European Society of Endocrinology (ESE) Conference 2022. Such initiatives are likely to generate more awareness of Addison’s disease testing, especially in the Europe region.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Country-wise Insights

Countries 2022 Value Share in Global Market
United States 31.1%
Germany 5.4%
Japan 4.2%

Is the United States Experiencing a Surge in Addison's Disease Cases?

The United States Addison disease testing market is a rapidly growing sector within the diagnostic industry. Addison's disease is primarily attributed to an autoimmune reaction, wherein the immune system inexplicably targets and damages healthy tissues. Addison's disease affects both males and females equally. The prevalence of this condition in the United States is around 1 in 100,000 people, with an estimated overall occurrence of 40 to 60 individuals per million in the general population.

The United States represents one of the leading markets for Addison disease testing globally. The United States has witnessed a significant increase in the prevalence of autoimmune disorders, including Addison's disease. This trend has resulted in a higher demand for accurate and reliable diagnostic tests, driving market growth. The country has a comprehensive healthcare system that includes favorable reimbursement policies for diagnostic tests. This encourages healthcare providers and patients to opt for Addison disease testing, contributing to market growth.

How Does Germany's Robust Healthcare Infrastructure Support Accurate Addison Disease Testing?

The Germany Addison disease testing market is witnessing growth due to increasing awareness, technological advancements, and robust healthcare infrastructure. Between 2008 and 2012, the prevalence of Addison's disease experienced a rise from 82 per million to 87 per million in Germany. On average, there was an annual increase of approximately 1.8%. Notably, the prevalence among females exhibited a more pronounced growth of 2.7%. Comparatively, the prevalence among males was lower, ranging from 63 to 68 per million, while in females, it ranged from 96 to 108 per million.

The medical diagnostics sector in Germany continues to benefit from advanced technologies. Innovations in immunoassays, genetic testing, and imaging techniques have improved the accuracy and efficiency of Addison disease testing, further driving market growth. Germany boasts a well-established and efficient healthcare system, with advanced medical facilities and a high standard of care. This infrastructure supports the accurate and timely diagnosis of Addison's disease, positively impacting the market.

Is Japan's Aging Population Fueling the Demand for Addison Disease Testing?

With one of the most rapidly aging populations in the world, Japan has a greater prevalence of chronic illnesses like Addison's disease. The aging population presents a significant market opportunity for Addison disease testing, as older individuals are at a higher risk of developing the condition. There is a growing emphasis on early disease detection in Japan's healthcare system. Consequently, there is an increasing demand for accurate and reliable diagnostic tests for early detection.

Patients in Japan are becoming more proactive in managing their health and seeking early diagnosis for various medical conditions. The growing patient awareness about the symptoms and consequences of Addison's disease drives the demand for diagnostic tests, contributing to market expansion. Japan has a well-developed healthcare system, and the government invests heavily in healthcare infrastructure and services. The high healthcare expenditure indicates a favorable environment for the growth of the Japan Addison disease testing market.

Countries Value CAGR (2023 to 2033)
United Kingdom 4.3%
China 6.4%
India 5.2%

What Technological Advancements are Revolutionizing the Addison Disease Testing Sector in the United Kingdom?

The United Kingdom Addison disease testing market has grown significantly in recent years. The country has seen a rise in the prevalence of Addison's disease in recent years. About 1 in 10,000 individuals are affected by Addison's disease, resulting in an estimated annual diagnosis of 300 to 350 new cases across the United Kingdom. As of 2023, Addison's disease is present in around 8,400 individuals in the country. While it can affect individuals of all ages, it is most frequently observed in the age range of 30 to 50. Additionally, it is more prevalent among women compared to men.

The concept of personalized medicine is gaining traction in the United Kingdom's healthcare sector, including the field of endocrinology. Physicians are increasingly adopting a patient-centric approach, tailoring treatments based on individual characteristics and genetic profiles. This trend is likely to impact the market, as personalized testing strategies may be employed to identify specific biomarkers and optimize treatment plans for patients with adrenal insufficiency. Advancements in diagnostic technologies have also revolutionized the market in the United Kingdom. Immunoassays, genetic testing, and molecular diagnostics have enabled more efficient detection of adrenal insufficiency.

How Can Patient Awareness Drive the Demand for Addison Disease Testing in China?

The China Addison disease testing market is poised for substantial growth driven by increasing awareness, healthcare reforms, and the rising prevalence of Addison's disease. Although Addison's disease is considered a rare condition worldwide, its prevalence is gradually increasing in China. This can be attributed to improved disease awareness, better access to healthcare, and enhanced screening methods.

The awareness of rare diseases among both healthcare professionals and the general population has been increasing in China. As a result, there has been a rise in early screening and diagnosis of rare conditions, contributing to the demand for Addison disease testing. China has been steadily increasing its healthcare spending to improve healthcare facilities and services across the country. This has led to a higher demand for advanced diagnostic tests, including those for rare diseases like Addison's disease.

What Role do Government Initiatives Play in Promoting Addison Disease Testing in India?

The incidence of Addison's disease in India has been gradually rising. Addison's disease can impact individuals of any gender and age group. The estimated prevalence of this condition is approximately 40-60 cases per million in the general population. In India, the disease is reported to affect about 1 in 100,000 people. The India Addison disease testing market is experiencing growth due to increased disease awareness, technological advancements, and improved healthcare infrastructure.

The adoption of point-of-care testing (POCT) devices for Addison's disease testing has gained momentum in India. POCT allows for rapid and convenient testing at the patient's location, resulting in reduced turnaround time and improved patient management. The Indian government has been implementing various programs to improve healthcare infrastructure and access, including the expansion of primary healthcare centers and the provision of free or subsidized diagnostic services. These initiatives can positively impact Addison's disease testing.

Category-wise Insights

Segment 2022 Value Share in Global Market
ACTH Stimulation Addison Disease Testing 23.4%
Hospitals 52.4%

ACTH Stimulation Emerges as the Preferred Method, Shaping the Future of Addison Disease Testing

The ACTH stimulation test is widely recognized as a highly reliable diagnostic method for adrenal insufficiency. This test involves the administration of a synthetic version of adrenocorticotropic hormone (ACTH) and the measurement of cortisol levels before and after its administration. Its purpose is to evaluate the adrenal glands' capacity to respond and produce cortisol.

By assessing the adrenal response to ACTH, the ACTH stimulation test can effectively differentiate between primary adrenal insufficiency (also known as Addison's disease) and secondary adrenal insufficiency caused by hypothalamic-pituitary dysfunction. This information enables healthcare providers to pinpoint the specific site of dysfunction within the adrenal axis.

The ACTH stimulation test holds significant importance and is recommended by medical guidelines and endocrinology associations for diagnosing adrenal insufficiency, including Addison's disease. These guidelines not only promote standardization but also encourage the widespread adoption of this testing method, ensuring its consistent and accurate use in clinical practice.

Hospitals Lead the Way in Addison Disease Testing, Ensuring Accurate Diagnoses

Hospitals boast robust infrastructure and specialized facilities that are crucial for conducting a wide array of diagnostic tests. With state-of-the-art laboratories and skilled staff, they possess the capability to perform an extensive range of tests, including those for Addison's disease.

Functioning as primary healthcare providers, hospitals cater to patients with diverse medical conditions, including endocrine disorders like Addison's disease. Consequently, they have a larger pool of potential patients who require diagnostic testing. This increased patient volume provides hospitals with a notable advantage, enabling them to conduct a significant number of Addison's disease tests.

One notable advantage of hospitals is their access to a diverse range of medical specialists, including experienced endocrinologists who possess extensive knowledge in diagnosing and treating conditions such as Addison's disease. These specialists work closely with laboratory services to ensure accurate interpretation of test results. This collaborative approach between specialists and testing facilities within hospitals significantly enhances the precision of diagnosing Addison's disease.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

The Start-up Ecosystem- How Key Disruptors are Calling the Shots?

While the Addison disease treatment landscape appears quite a niche, a host of start-ups have capitalized on this opportunity to introduce novel treatment, diagnostic and therapeutic approaches across the world.

Some notable start-ups offering Addison disease treatment are as follows:

  • Addison Care
  • SameDay Security
  • Vitruvian BioMedical
  • Addison Care offers a virtual health assistant for managing weight or chronic illness. The company offers smart devices weight scales, non-contact thermometers, glucose meters, blood pressure cuffs, and pulse oximeters. For tracking health data. The platform provides reminders to measure the vitals, tracks the data from the devices, and uses AI to analyze the health data.
  • In January 2019, SameDay Security secured $32 million in a Series D fundraising round, which will help in the development and rollout of Addison - a virtual caregiver that could be deployed in senior living to extend the length of stay.

Who are the Key Players in the Global Addison Disease Testing Market?

Some of the players in the Addison Disease Testing service market involve Diagnostic Laboratory Services, Inc., Any Lab Test Now, Dr. Lal PathLabs, Laboratory Corporation of America Holdings, Sonora Quest Laboratories, Core Diagnostics Private Limited, Ayumetrix, and others.

  • In May 2021, AdrenalinMD launched a home testing kit for Addison's disease. This kit allows people to test their own blood levels of cortisol and ACTH, and it can be used to diagnose Addison's disease or to monitor treatment.
  • In January 2020, the FDA approved a new blood test called the Synacthen Depot Test for the diagnosis of Addison's disease. This test is more accurate than the traditional ACTH stimulation test, and it can be performed in a doctor's office.
  • In February 2020, Dr. Lal PathLabs Ltd, a Gurugram-based public diagnostics chain, spent around Rs 7.7 crore (a little over $1 million at the current exchange rate) to acquire two pathological laboratories in Maharashtra.
  • In February 2021, Genalyte, a healthcare diagnostics and analytics company, and Sonora Quest Laboratories, the market share leader in diagnostic laboratory testing in Arizona, announced a strategic partnership with Cigna Medicare Arizona to leverage science-based analytics to reduce costs while improving clinical outcomes for customers of Cigna Arizona's Medicare Advantage plans.

Key Market Players

  • Diagnostic Laboratory Services Inc.
  • Any Lab Test Now
  • Dr. Lal PathLabs
  • Laboratory Corporation of America Holdings
  • Sonora Quest Laboratories
  • Core Diagnostics Private Limited
  • Ayumetrix

Key Segments Covered in the Addison Disease Testing Industry Survey

By Testing Type:

  • Laboratory
  • Comprehensive Metabolic Panel
  • Thyroid-Stimulating Hormone (TSH) Levels
  • ACTH Stimulation
  • Insulin-induced Hypoglycaemia
  • Autoantibody
  • Prolactin
  • Imaging Studies
  • Chest Radiograph
  • Computed tomography (CT) Scan

By End User:

  • Hospitals
  • Clinics
  • Diagnostics Laboratories

By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Middle East & Africa
  • Latin America

Frequently Asked Questions

What is the growth rate of the market until 2033?

By 2033, the market will expand at a 3.4% CAGR.

What is the 2023 market value?

The 2023 market value is US$ 249.8 million.

What was the historical CAGR of the market?

From 2018 to 2022, the market expanded at a 2.2% CAGR.

What is the market value for 2033?

By 2033, the market will reach US$ 349.7 million.

Who are some prominent market players?

Sonora Quest Laboratories, Core Diagnostics Private Limited, Ayumetrix are some key players.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Testing Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Testing Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Testing Type, 2023 to 2033

        5.3.1. Laboratory Addison Disease Testing

        5.3.2. Comprehensive Metabolic Panel Addison Disease Testing

        5.3.3. Thyroid-Stimulating Hormone (TSH) Levels Addison Disease Testing

        5.3.4. ACTH Stimulation Addison Disease Testing

        5.3.5. Insulin-induced Hypoglycaemia Addison Disease Test

        5.3.6. Autoantibody Addison Disease Testing

        5.3.7. Prolactin Addison Disease Testing

        5.3.8. Imaging Studies Addison Disease Testing

        5.3.9. Chest Radiograph Addison Disease Testing

        5.3.10. Computed tomography (CT) Scan Addison Disease Testing

    5.4. Y-o-Y Growth Trend Analysis By Testing Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Testing Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Diagnostics Laboratories

    6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Western Europe

        7.3.4. Eastern Europe

        7.3.5. South Asia and Pacific

        7.3.6. East Asia

        7.3.7. Middle East and Africa

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. USA

            8.2.1.2. Canada

        8.2.2. By Testing Type

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Testing Type

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Testing Type

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Testing Type

        9.3.3. By End User

    9.4. Key Takeaways

10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. UK

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Western Europe

        10.2.2. By Testing Type

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Testing Type

        10.3.3. By End User

    10.4. Key Takeaways

11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Poland

            11.2.1.2. Russia

            11.2.1.3. Czech Republic

            11.2.1.4. Romania

            11.2.1.5. Rest of Eastern Europe

        11.2.2. By Testing Type

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Testing Type

        11.3.3. By End User

    11.4. Key Takeaways

12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Bangladesh

            12.2.1.3. Australia

            12.2.1.4. New Zealand

            12.2.1.5. Rest of South Asia and Pacific

        12.2.2. By Testing Type

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Testing Type

        12.3.3. By End User

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Testing Type

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Testing Type

        13.3.3. By End User

    13.4. Key Takeaways

14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. GCC Countries

            14.2.1.2. South Africa

            14.2.1.3. Israel

            14.2.1.4. Rest of MEA

        14.2.2. By Testing Type

        14.2.3. By End User

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Testing Type

        14.3.3. By End User

    14.4. Key Takeaways

15. Key Countries Market Analysis

    15.1. USA

        15.1.1. Pricing Analysis

        15.1.2. Market Share Analysis, 2022

            15.1.2.1. By Testing Type

            15.1.2.2. By End User

    15.2. Canada

        15.2.1. Pricing Analysis

        15.2.2. Market Share Analysis, 2022

            15.2.2.1. By Testing Type

            15.2.2.2. By End User

    15.3. Brazil

        15.3.1. Pricing Analysis

        15.3.2. Market Share Analysis, 2022

            15.3.2.1. By Testing Type

            15.3.2.2. By End User

    15.4. Mexico

        15.4.1. Pricing Analysis

        15.4.2. Market Share Analysis, 2022

            15.4.2.1. By Testing Type

            15.4.2.2. By End User

    15.5. Germany

        15.5.1. Pricing Analysis

        15.5.2. Market Share Analysis, 2022

            15.5.2.1. By Testing Type

            15.5.2.2. By End User

    15.6. UK

        15.6.1. Pricing Analysis

        15.6.2. Market Share Analysis, 2022

            15.6.2.1. By Testing Type

            15.6.2.2. By End User

    15.7. France

        15.7.1. Pricing Analysis

        15.7.2. Market Share Analysis, 2022

            15.7.2.1. By Testing Type

            15.7.2.2. By End User

    15.8. Spain

        15.8.1. Pricing Analysis

        15.8.2. Market Share Analysis, 2022

            15.8.2.1. By Testing Type

            15.8.2.2. By End User

    15.9. Italy

        15.9.1. Pricing Analysis

        15.9.2. Market Share Analysis, 2022

            15.9.2.1. By Testing Type

            15.9.2.2. By End User

    15.10. Poland

        15.10.1. Pricing Analysis

        15.10.2. Market Share Analysis, 2022

            15.10.2.1. By Testing Type

            15.10.2.2. By End User

    15.11. Russia

        15.11.1. Pricing Analysis

        15.11.2. Market Share Analysis, 2022

            15.11.2.1. By Testing Type

            15.11.2.2. By End User

    15.12. Czech Republic

        15.12.1. Pricing Analysis

        15.12.2. Market Share Analysis, 2022

            15.12.2.1. By Testing Type

            15.12.2.2. By End User

    15.13. Romania

        15.13.1. Pricing Analysis

        15.13.2. Market Share Analysis, 2022

            15.13.2.1. By Testing Type

            15.13.2.2. By End User

    15.14. India

        15.14.1. Pricing Analysis

        15.14.2. Market Share Analysis, 2022

            15.14.2.1. By Testing Type

            15.14.2.2. By End User

    15.15. Bangladesh

        15.15.1. Pricing Analysis

        15.15.2. Market Share Analysis, 2022

            15.15.2.1. By Testing Type

            15.15.2.2. By End User

    15.16. Australia

        15.16.1. Pricing Analysis

        15.16.2. Market Share Analysis, 2022

            15.16.2.1. By Testing Type

            15.16.2.2. By End User

    15.17. New Zealand

        15.17.1. Pricing Analysis

        15.17.2. Market Share Analysis, 2022

            15.17.2.1. By Testing Type

            15.17.2.2. By End User

    15.18. China

        15.18.1. Pricing Analysis

        15.18.2. Market Share Analysis, 2022

            15.18.2.1. By Testing Type

            15.18.2.2. By End User

    15.19. Japan

        15.19.1. Pricing Analysis

        15.19.2. Market Share Analysis, 2022

            15.19.2.1. By Testing Type

            15.19.2.2. By End User

    15.20. South Korea

        15.20.1. Pricing Analysis

        15.20.2. Market Share Analysis, 2022

            15.20.2.1. By Testing Type

            15.20.2.2. By End User

    15.21. GCC Countries

        15.21.1. Pricing Analysis

        15.21.2. Market Share Analysis, 2022

            15.21.2.1. By Testing Type

            15.21.2.2. By End User

    15.22. South Africa

        15.22.1. Pricing Analysis

        15.22.2. Market Share Analysis, 2022

            15.22.2.1. By Testing Type

            15.22.2.2. By End User

    15.23. Israel

        15.23.1. Pricing Analysis

        15.23.2. Market Share Analysis, 2022

            15.23.2.1. By Testing Type

            15.23.2.2. By End User

16. Market Structure Analysis

    16.1. Competition Dashboard

    16.2. Competition Benchmarking

    16.3. Market Share Analysis of Top Players

        16.3.1. By Regional

        16.3.2. By Testing Type

        16.3.3. By End User

17. Competition Analysis

    17.1. Competition Deep Dive

        17.1.1. Diagnostic Laboratory Services Inc.

            17.1.1.1. Overview

            17.1.1.2. Product Portfolio

            17.1.1.3. Profitability by Market Segments

            17.1.1.4. Sales Footprint

            17.1.1.5. Strategy Overview

                17.1.1.5.1. Marketing Strategy

        17.1.2. Any Lab Test Now

            17.1.2.1. Overview

            17.1.2.2. Product Portfolio

            17.1.2.3. Profitability by Market Segments

            17.1.2.4. Sales Footprint

            17.1.2.5. Strategy Overview

                17.1.2.5.1. Marketing Strategy

        17.1.3. Dr. Lal PathLabs

            17.1.3.1. Overview

            17.1.3.2. Product Portfolio

            17.1.3.3. Profitability by Market Segments

            17.1.3.4. Sales Footprint

            17.1.3.5. Strategy Overview

                17.1.3.5.1. Marketing Strategy

        17.1.4. Laboratory Corporation of America Holdings

            17.1.4.1. Overview

            17.1.4.2. Product Portfolio

            17.1.4.3. Profitability by Market Segments

            17.1.4.4. Sales Footprint

            17.1.4.5. Strategy Overview

                17.1.4.5.1. Marketing Strategy

        17.1.5. Sonora Quest Laboratories

            17.1.5.1. Overview

            17.1.5.2. Product Portfolio

            17.1.5.3. Profitability by Market Segments

            17.1.5.4. Sales Footprint

            17.1.5.5. Strategy Overview

                17.1.5.5.1. Marketing Strategy

        17.1.6. Core Diagnostics Private Limited

            17.1.6.1. Overview

            17.1.6.2. Product Portfolio

            17.1.6.3. Profitability by Market Segments

            17.1.6.4. Sales Footprint

            17.1.6.5. Strategy Overview

                17.1.6.5.1. Marketing Strategy

        17.1.7. Ayumetrix

            17.1.7.1. Overview

            17.1.7.2. Product Portfolio

            17.1.7.3. Profitability by Market Segments

            17.1.7.4. Sales Footprint

            17.1.7.5. Strategy Overview

                17.1.7.5.1. Marketing Strategy

        17.1.8. VCA Animal Hospital

            17.1.8.1. Overview

            17.1.8.2. Product Portfolio

            17.1.8.3. Profitability by Market Segments

            17.1.8.4. Sales Footprint

            17.1.8.5. Strategy Overview

                17.1.8.5.1. Marketing Strategy

        17.1.9. National Organization for Rare Disorders

            17.1.9.1. Overview

            17.1.9.2. Product Portfolio

            17.1.9.3. Profitability by Market Segments

            17.1.9.4. Sales Footprint

            17.1.9.5. Strategy Overview

                17.1.9.5.1. Marketing Strategy

        17.1.10. NIDDK

            17.1.10.1. Overview

            17.1.10.2. Product Portfolio

            17.1.10.3. Profitability by Market Segments

            17.1.10.4. Sales Footprint

            17.1.10.5. Strategy Overview

                17.1.10.5.1. Marketing Strategy

18. Assumptions & Acronyms Used

19. Research Methodology

Recommendations

Healthcare

Legionnaire Disease Testing Market

September 2019

REP-GB-10399

June 2022

342 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Addison Disease Testing Market